CUE · short Cue Biopharma
Cue Biopharma faces a deteriorating balance sheet, recurring operating losses, ATM dilution and PIPE-investor selling pressure.
NASDAQ
Cue Biopharma, Inc.
CUE
1 story
$162M Market cap · 2026-10-08
CUE · short CUE · short 